Medical device manufacturer BSN medical has introduced six new wound care products, of which three products feature the firm’s dialkylcarbamoylchloride (DACC) technology.
DACC Technology is said to bind bacteria, rendering it inert and reduces the bacteria load in the wound bed.
The DACC Technology featured products include Cutimed sorbact hydroactive B dressing, which has been developed for effective fluid management on wounds with low to moderate exudate levels.
BSN has developed the Cutimed siltec sorbact foam dressing that aggregates DACC technology with siltec foam structure to rapidly absorb and draw fluid into super absorbent particles for less risk of peri-wound maceration.
The Leukomed sorbact is a post-operative dressing that features wound contact layer (WCL) with DACC technology, allowing the dressing to effectively bind bacteria and fungi without a chemically active agent and reduces the risk of infection and maintains a favorable healing environment.
Connecticut Clinical Nursing Associates co-owner Catherine Milne said: "BSN medical’s DACC Technology addresses multiple complexities found in a variety of chronic wounds because it treats both topical wounds and the underlying cause."
The company will exhibit the new wound care solutions at the Symposium on Advanced Wound Care (SAWC Spring) in San Antonio, Texas.
Based in Hamburg of Germany, BSN medical produces wound care and non-invasive vascular solutions, including compression therapy and orthopaedics comprising fracture management and soft goods.